Ataibeckley Inc. (ATAI) Stock Price & Analysis
Ataibeckley Inc. (ATAI) rose 2.10% to USD 3.89 as of June 10, 2026 at 12:24 UTC, according to Nexqual real-time market data.
ATAI last closed at USD 3.81; the session ranged USD 3.76–4.01 on volume of 5,312,923 shares. Market capitalization is $1.43B, with a 52-week range of USD 2–6.75 (NGM). Source: Nexqual, June 10, 2026 at 12:24 UTC.
Key Statistics (as of June 10, 2026 at 12:24 UTC)
| Price | USD 3.89 |
|---|---|
| Change | ▲ 2.10% (up) |
| Previous Close | USD 3.81 |
| Open | USD 3.83 |
| Day Range | USD 3.76 – 4.01 |
| 52-Week Range | USD 2 – 6.75 |
| Volume | 5,312,923 shares |
| Market Cap | $1.43B |
| Exchange | NGM |
Technical Analysis (ATAI)
Nexqual's technical model rates ATAI "SELL" based on 2 bullish and 4 bearish signals across 123 daily candles, as of June 10, 2026 at 12:24 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 33.87 (neutral) |
| vs SMA50 | Below (USD 4.14) |
| MACD | 0.03 (positive) |
Analyst Ratings (ATAI)
Wall Street analysts rate ATAI "Strong Buy" based on 12 analysts, with a mean price target of USD 14 (range USD 7–25), per Nexqual as of June 10, 2026 at 12:24 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 14 |
| High Target | USD 25 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 14 / 0 / 0 |
Earnings (ATAI)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.11 |
| Revenue Estimate | $83,330 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -1.73 vs est -0.11 ▼ miss |
| 2025-09-30 | USD -0.28 vs est -0.12 ▼ miss |
| 2025-06-30 | USD -0.14 vs est -0.12 ▼ miss |
Source: Nexqual, June 10, 2026 at 12:24 UTC.
Financials & Fundamentals (ATAI)
| Total Revenue | $3.49M |
|---|---|
| Revenue Growth (YoY) | -38.70% |
| Gross Margin | +0.00% |
| Operating Margin | -3239.10% |
| Profit Margin | +0.00% |
| ROE | -378.00% |
| Debt / Equity | 1.01 |
| Current Ratio | 10.02 |
| Total Cash | $230.77M |
| Total Debt | $2.00M |
Source: Nexqual, June 10, 2026 at 12:24 UTC.
Financial Health Score (ATAI)
Nexqual rates Ataibeckley Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 12:24 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $231M cash vs $2M debt, net cash position |
| Cash Flow | Mixed — No data |
| Efficiency | Critical — ROE -378%, ROA -33.0% |
Ownership (ATAI)
| Insider Ownership | +2.35% |
|---|---|
| Institutional Ownership | +43.51% |
| Shares Outstanding | 368.17M |
| Float | 297.13M |
| Short % of Float | +6.99% |
Source: Nexqual, June 10, 2026 at 12:24 UTC.
Leadership (ATAI)
Ataibeckley Inc. is led by Srinivas G. Rao (age 56), Co-Founder, CEO & Executive Director, per Nexqual as of June 10, 2026 at 12:24 UTC.
| Co-Founder, CEO & Executive Director | Srinivas G. Rao (age 56) |
|---|---|
| Co-Founder & Chairman of the Board | Christian Angermayer (age 47) |
| Chief Operating Officer | Gerd G. Kochendoerfer (age 57) |
| Chief Financial Officer | Michael Eric Faerm (age 58) |
| Chief Scientific Officer | Glenn Short (age 55) |
Major Backers & Investors (ATAI)
Notable institutional backers of Ataibeckley Inc. include Deep Track Capital, Lp, UBS Group AG, Adage Capital Partners GP L.L.C., according to Nexqual as of June 10, 2026 at 12:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Deep Track Capital, Lp | 3.26% |
| UBS Group AG | 2.02% |
| Adage Capital Partners GP L.L.C. | 1.53% |
| Susquehanna International Group, LLP | 1.44% |
| Morgan Stanley | 1.27% |
| Millennium Management | 1.19% |
| ARK Invest | 1.09% |
| Candriam S.C.A. | 0.84% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.3% |
| BlackRock | 2.44% |
Source: Nexqual, June 10, 2026 at 12:24 UTC.
From Ataibeckley Inc.'s Latest SEC 10-K Filing (filed 2026-03-06)
Key Strengths & Strategy (as disclosed to the SEC)
- In addition, there have been recent developments in the treatment of MDD, including AUVELITY (dextromethorphan/bupropion), a therapeutic marketed by Axsome Therapeutics, which was approved by the FDA in August 2022 and CAPLYTA (lumateperone, a therapeutic originally developed by Intra-Cellular Therapies (now Johnson & Johnson) and approved by the FDA in November 2025.
- We seek to protect our proprietary information, in part, by executing confidentiality agreements with our collaborators and scientific advisors, and non-competition, non-solicitation, confidentiality, and invention assignment agreements with our employees, consultants, and independent contractors.
- The confidentiality agreements we enter into are designed to protect our proprietary information, and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of technologies that are developed through our relationship with the respective counterparty.
- We have built a diversified pipeline of investigational psychedelic-based neuroplastogens designed to address some of the most urgent unmet needs in mental health.
Partnerships
- Even among patients who access care, treatment adequacy remains suboptimal, and around 50% of SAD patients do not achieve adequate response to first line therapies and often deal with chronic medication side effects.
- Atai Therapeutics, Inc. has a strategic investment in Amandala Neuro Limited to accelerate the clinical development of short-duration psychedelics.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GHRS | GH Research PLC | USD 20.35 | ▼ 5.04% |
| CMPS | COMPASS Pathways Plc - American | USD 11.26 | ▼ 7.02% |
| HELP | Cybin Inc. | USD 3.92 | ▼ 5.54% |
| IXHL | Incannex Healthcare Inc. | USD 3.67 | ▲ 25.68% |
| PBM | Psyence Biomedical Ltd. | USD 3.33 | ▼ 5.13% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 12:24 UTC. This page is informational and not investment advice.